My research focuses on understanding how the immune system interacts with viruses and cancer, with the goal of developing new therapeutic strategies. My work spans three interconnected areas: oncolytic virotherapy, antiviral drug development, and molecular virology.

Currently, I investigate how oncolytic viruses - viruses that selectively target and kill cancer cells - can be harnessed as a treatment for aggressive cancers. Using CRISPR-based screening approaches combined with molecular cloning and viral engineering, I aim to identify and functionally characterize the host factors that determine whether cancer cells are susceptible or resistant to this type of therapy, with a particular focus on rare and difficult-to-treat pediatric cancers.

Earlier in my career, I developed and evaluated novel antiviral nanotherapeutics for HIV, combining polymer chemistry with virology to design long-acting drug delivery systems. This work demonstrated the potential of engineered macromolecules as next-generation antiretroviral treatments.

My research integrates molecular biology techniques, including cloning, viral vector production, and CRISPR/Cas9-mediated genome editing, with mouse models of human disease and bioinformatics to bridge basic science and translational medicine. A central theme across my work is leveraging the biology of viruses, both as targets for therapy and as tools for therapeutic intervention.